ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

Showing results for FDA

March 30, 2020

In testimony submitted to Congress about the federal budget for FY 2021, ASCO thanked lawmakers for increasing funding for cancer research in FY2020 and urged them  to increase funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the Centers for Disease Control and Protection (CDC) in the year ahead.

March 30, 2020

On March 27, 2020, the Food and Drug Administration approved durvalumab (IMFINZI®, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

March 18, 2020

The U.S. Food and Drug Administration today issued a guidance for industry, investigators and institutional review boards conducting clinical trials during the coronavirus (COVID-19) pandemic.

March 11, 2020

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.

March 9, 2020

“We commend the U.S. Food and Drug Administration (FDA) for releasing draft guidance to encourage inclusion of older adults in clinical trials of drugs for the treatment of cancer. We thank Richard Pazdur, MD, director of the FDA Oncology Center of Excellence, for his leadership on this important issue.

March 2, 2020

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.

February 26, 2020

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.

February 18, 2020
On February 11, members of the Association for Clinical Oncology’s (ASCO) Government Relations Committee met with several federal agencies and stakeholder groups to discuss top cancer policy priorities.

The meetings focused on drug pricing, access to clinical trials, Medicaid expansion and block grants, accelerated drug approval pathways, and other issues affecting people with cancer and their oncology care teams.

February 4, 2020

The American Society of Clinical Oncology (ASCO) Research Community Forum (RCF) is holding a free, two-part webinar on Food and Drug Administration (FDA) audit readiness, which will take participants on a journey through the FDA inspection process. 

February 4, 2020

The Centers for Medicare & Medicaid Services (CMS) announced that it is expanding its coverage of next generation sequencing (NGS) for use as a diagnostic tool for certain patients with cancer.

January 24, 2020

On January 23, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK™, Epizyme, Inc.) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

January 21, 2020

As part of the Administration’s push to lower prescription drug prices, the Food and Drug Administration (FDA) released a proposed rule and draft guidance on drug importation into the Unites States (U.S.). The proposed rule would authorize states, wholesalers, or pharmacists to submit proposals to import prescription drugs from Canada into the U.S. The rule, however, would exclude the importation of biologics and infused drugs.

January 9, 2020

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.

January 8, 2020

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.

January 7, 2020

The Food and Drug Administration (FDA) recently issued a ban on flavored e-cigarette pods, except for those that are menthol and tobacco flavored. Despite pressure for a comprehensive ban from the anti-smoking community, the FDA rule, as written, will affect a relatively small portion of the vaping industry. It will only apply to cartridge-based products, leaving larger, tank-style vapes exempt from the ban. Single use and disposable vapes, which are becoming increasingly popular among children, are also exempt.

Pages